This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||IPAS / iPass, Inc. (46261V108)|
|Industry||Computer Processing and Data Preparation and Processing Services|
|Institutional Shares||13,830,285 - 16.47%|
|Common Shares Outstanding||83,978,957 shares (as of 2018-06-30)|
|Institutional Value||$ 5,399,000 USD|
Institutional Stock Ownership and Shareholders()
iPass, Inc. (NASDAQ:IPAS) has 39 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,830,285 shares.
Largest shareholders include
Renaissance Technologies LLC, Vanguard Group Inc, Pratt Collard Advisory Partners Llc, Perkins Capital Management Inc, Manatuck Hill Partners, LLC, Goldman Capital Management Inc, Emancipation Management LLC, Geode Capital Management, Llc, Eidelman Virant Capital, and California Public Employees Retirement System.
iPass, Inc. (NASDAQ:IPAS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|Manatuck Hill Partners, LLC||450,000||1,050,000||133.33||171||362||111.70|
|UBS Group AG||22,525||19,371||-14.00||8||7||-12.50|
|AMG National Trust Bank||49,570||49,570||0.00||19||17||-10.53|
|STATE STREET CORP||27,610||27,610||0.00||10||8||-20.00|
|PERKINS CAPITAL MANAGEMENT INC||1,642,471||566|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||26,934||67,078||149.05||10||23||130.00|
|JACOBS LEVY EQUITY MANAGEMENT, INC||452,065||0||-100.00||172||0||-100.00|
|EARNEST PARTNERS LLC||7,700||7,700||0.00||3||3||0.00|
|Emancipation Management LLC||0||576,802||0||199|
|UNITED SERVICES AUTOMOBILE ASSOCIATION||12,564||12,564||0.00||5||4||-20.00|
|Acrospire Investment Management LLC||2,642||0||-100.00||3||0||-100.00|
|BlackRock Investment Management, LLC||11,385||11,385||0.00||19||19||0.00|
|Adirondack Research & Management Inc.||814,742||30,366||-96.27||310||10||-96.77|
|Marathon Capital Management||42,035||50,000||18.95||15||17||13.33|
|One Wealth Advisors, Llc||76,700||76,700||0.00||29||26||-10.34|
|GUGGENHEIM CAPITAL LLC||23,735||0||-100.00||9||0||-100.00|
|NOMURA HOLDINGS INC||41,226||41,226||0.00||16||14||-12.50|
|Renaissance Technologies LLC||3,291,898||1,251|
|Advisor Group, Inc.||0||8,800||0||3|
|M&R CAPITAL MANAGEMENT INC||15,000||15,000||0.00||5||5||0.00|
|BlackRock Institutional Trust Company, N.A.||86,574||86,574||0.00||141||143||1.42|
|GABELLI FUNDS LLC||50,000||0||-100.00||19||0||-100.00|
|Pratt Collard Advisory Partners Llc||1,654,520||1,790,120||8.20||629||617||-1.91|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||351,470||351,470||0.00||134||121||-9.70|
|JANE STREET GROUP, LLC||0||32,291||0||11|
|Commonwealth Equity Services, Inc||38,738||38,738||0.00||51||26||-49.02|
|BRIDGEWAY CAPITAL MANAGEMENT INC||99,900||95,300||-4.60||38||33||-13.16|
|WELLS FARGO & COMPANY/MN||0||0||0||0|
|Mccollum Christoferson Group Llc||40,000||65,000||62.50||15||22||46.67|
|Paragon Capital Management Ltd||16,667||16,667||0.00||6||6||0.00|
|Bank of New York Mellon Corp||66,541||53,977||-18.88||26||19||-26.92|
|BlackRock Fund Advisors||177,212||182,136||2.78||289||301||4.15|
|Eidelman Virant Capital||650,000||400,000||-38.46||247||137||-44.53|
|Commonwealth Equity Services, Llc.||48,738||48,738||0.00||18||17||-5.56|
|Royce & Associates LLC||948,500||0||-100.00||360||0||-100.00|
|Capital Bank & Trust Co||7,035||7,035||0.00||3||2||-33.33|
|GEODE CAPITAL MANAGEMENT, LLC||474,363||474,363||0.00||180||163||-9.44|
|GOLDMAN CAPITAL MANAGEMENT INC||1,301,000||801,000||-38.43||859||417||-51.46|
|VANGUARD GROUP INC||2,297,739||2,055,405||-10.55||873||709||-18.79|
|WHITE PINE CAPITAL LLC||35,000||35,000||0.00||13||12||-7.69|
|NORTHERN TRUST CORP||134,197||134,197||0.00||51||46||-9.80|
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
The following slide deck was published by iPass Inc. in conjunction with their 2018 Q2 earnings call. (2-2)
Good day. And welcome to the iPass Inc. Second Quarter 2018 Financial Results Conference Call. Today's conference is being recorded. (3-2)
Good day. And welcome to the iPass First Quarter 2018 Financial Results Conference Call. Today's conference is being recorded. (15-0)
The following slide deck was published by iPass Inc. in conjunction with their 2018 Q1 earnings call. (15-1)
* IPASS INC - ANNOUNCED A DEAL WITH LYCAMOBILE TO PROVIDE GLOBAL WI-FI TO ITS MONTHLY PLAN CUSTOMERS (15-4)
Silicon Investor Message Boards
This table lists all message boards related to IPAS / iPass, Inc. on message board site Silicon Investor.
|iPASS Stock Discussion||iPASS Stock Discussion||iPASS Stock Discussion|
as of ET